Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received an average rating of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $10.28.

MRVI has been the subject of several research reports. Guggenheim began coverage on Maravai LifeSciences in a research report on Thursday, December 19th. They set a “neutral” rating for the company. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. Robert W. Baird decreased their price objective on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Finally, Royal Bank of Canada decreased their price target on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Carl Hull acquired 175,000 shares of the stock in a transaction on Monday, November 11th. The shares were acquired at an average price of $5.64 per share, with a total value of $987,000.00. Following the purchase, the insider now owns 175,000 shares in the company, valued at $987,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning increased its stake in Maravai LifeSciences by 4.4% during the third quarter. Creative Planning now owns 44,943 shares of the company’s stock valued at $373,000 after purchasing an additional 1,881 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Maravai LifeSciences by 7.3% in the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock valued at $180,000 after buying an additional 2,239 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Maravai LifeSciences by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company’s stock valued at $164,000 after buying an additional 2,851 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its stake in Maravai LifeSciences by 0.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock worth $4,320,000 after acquiring an additional 3,725 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Maravai LifeSciences in the third quarter worth about $47,000. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Trading Down 3.4 %

NASDAQ:MRVI opened at $4.77 on Wednesday. Maravai LifeSciences has a 12-month low of $4.28 and a 12-month high of $11.56. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock’s 50 day simple moving average is $5.40 and its 200-day simple moving average is $7.07. The firm has a market cap of $1.20 billion, a P/E ratio of -2.91 and a beta of -0.08.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.09) EPS for the quarter. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business had revenue of $65.20 million during the quarter, compared to analyst estimates of $67.58 million. During the same period in the prior year, the business earned ($0.02) earnings per share. Equities analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.